inflammation of the liver viral hepatitis
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - male of female - 18 years or older - MSM or heterosexual - HIV positive of HIV negative - acute HCV infection - written informed consent
Exclusion criteria
Exclusion criteria: - no follow-up of patient at an HIV or Hepatology outpatient clinic - inability or unwillingness to provide informed consent or follow the requirements of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 Frequency and determinants of acquiring primary , re- and superinfection with HCV (sociodemographic, clinical, behavioural, virological, immunological and genetic variables) 2 A: HCV viral load dynamics according to treatment status and other determinants B: Proportion of patients with Rapid Virological Response (RVR), Early Virological Response (EVR) and Sustained Virological Response (SVR), defined by current and future (inter)national guidelines, according to weeks of treatment or weeks post therapy C: Predictors for Virological Response 3 A: Morbidity following acute HCV and its determinants in HIV infected and HIV-uninfected individuals B: Mortality following acute HCV and its determinants in HIV infected and HIV-uninfected individuals 4 Overlap between HIV and HCV epidemics 5 Driving factors for the HCV outbreak including sociodemographic, behavioural and biological variables | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. A: Probability of achieving HCV clearance in the absence of therapy B: Predictors of HCV clearance based on sociodemographic, clinical, virological, immunological and genetic variables 2. HCV-specific immunology: T-cells, B-cells and the innate responses 3. Time to HCV antibody seroconversion and its determinants 4. Response to cART in HIV/acute HCV coinfection, defined as short-term changes in HIV RNA and CD4 count levels 5. Liver fibrosis progression based on fibroscan, echo, biopsy and non invasive blood test scores 6. A: Risk behaviour before and after acute HCV infection and/or HCV treatment based on variables concerning sexual risk taking and drug use B: Quality of life after acute HCV infection and before, during and after HCV treatment 7. Further spread of HCV by sexual transmission and the impact of awareness, early diagnosis and treatment on this (within mathematical models) 8. Level of clustering of HCV based on sequence data 9. Host genetic factors for susceptibility and outcome of acute HCV infection | — |
Countries
Netherlands
Outcome results
None listed